Beyond platinum treatment for NSCLC: what does the future hold?

Mariacarmela Santarpia¹, Niki Karachaliou², Rafael Rosell^{3

4

5}

Affiliations

¹ a Medical Oncology Unit, Department of Human Pathology 'G. Barresi' , University of Messina , Messina , Italy.
² b Institute of Oncology Rosell (IOR) , University Hospital Sagrat Cor , Barcelona , Spain.
³ c Institute of Oncology Rosell (IOR), Quirón-Dexeus University Institute , Barcelona , Spain.
⁴ d Cancer Biology & Precision Medicine Program , Catalan Institute of Oncology, Hospital Germans Trias i Pujol , Badalona , Barcelona , Spain.
⁵ e Cellular and Molecular Biology Laboratory, Germans Trias i Pujol Health Sciences Institute and Hospital , Badalona , Barcelona , Spain.

Editorial

Mariacarmela Santarpia et al. Expert Rev Anticancer Ther. 2017 Apr.

. 2017 Apr;17(4):293-295.

doi: 10.1080/14737140.2017.1288103. Epub 2017 Feb 8.

Mariacarmela Santarpia¹, Niki Karachaliou², Rafael Rosell^{3

4

5}

¹ a Medical Oncology Unit, Department of Human Pathology 'G. Barresi' , University of Messina , Messina , Italy.
² b Institute of Oncology Rosell (IOR) , University Hospital Sagrat Cor , Barcelona , Spain.
³ c Institute of Oncology Rosell (IOR), Quirón-Dexeus University Institute , Barcelona , Spain.
⁴ d Cancer Biology & Precision Medicine Program , Catalan Institute of Oncology, Hospital Germans Trias i Pujol , Badalona , Barcelona , Spain.
⁵ e Cellular and Molecular Biology Laboratory, Germans Trias i Pujol Health Sciences Institute and Hospital , Badalona , Barcelona , Spain.

No abstract available

Keywords: Non-small cell lung cancer (NSCLC); immune checkpoint blockade; immunotherapy; nivolumab; pembrolizumab.

Publication types